

Unless otherwise defined herein, capitalized terms in this announcement shall have the same meanings as those defined in the prospectus dated December 7, 2017 (the “**Prospectus**”) issued by AK Medical Holdings Limited (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”). The Shares may not be offered or sold in the United States except pursuant to an effective registration statement or an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Shares in the United States.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities of the Company. Potential investors should read the Prospectus for detailed information about the Company before deciding whether or not to invest in the Shares thereby offered.



AK MEDICAL HOLDINGS LIMITED

愛康醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1789)

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on January 11, 2018, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The stabilizing actions undertaken by Goldman Sachs (Asia) L.L.C., the Stabilizing Manager and the Sole Global Coordinator, or any person acting for it, during the stabilization period involved:

- (1) over-allocations of an aggregate of 37,500,000 Shares in the International Placing, representing 15% of the Offer Shares initially available under the Global Offering;
- (2) borrowing of an aggregate of 37,500,000 Shares by the Stabilizing Manager (through its agent) from Ximalaya, a controlling shareholder of the Company, to cover the over-allocations in the International Placing; and
- (3) the full exercise of the Over-Allotment Option by the Sole Global Coordinator (on behalf of the International Underwriters) on December 27, 2017 (after trading hours) in respect of 37,500,000 additional new Shares, representing 15% of the Offer Shares initially available under the Global Offering before any exercise of the Over-Allotment Option, at the Offer Price per Share, to facilitate the return to Ximalaya of the 37,500,000 borrowed Shares which were used to cover the over-allocations in the International Placing.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces, pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), that the stabilization period in connection with the Global Offering ended on January 11, 2018, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The stabilizing actions undertaken by Goldman Sachs (Asia) L.L.C., the Stabilizing Manager and the Sole Global Coordinator, or any person acting for it, during the stabilization period involved:

- (1) over-allocations of an aggregate of 37,500,000 Shares in the International Placing, representing 15% of the Offer Shares initially available under the Global Offering;
- (2) borrowing of an aggregate of 37,500,000 Shares by the Stabilizing Manager (through its agent) from Ximalaya, a controlling shareholder of the Company, to cover the over-allocations in the International Placing; and
- (3) the full exercise of the Over-Allotment Option by the Sole Global Coordinator (on behalf of the International Underwriters) on December 27, 2017 (after trading hours) in respect of 37,500,000 additional new Shares, representing 15% of the Offer Shares initially available under the Global Offering before any exercise of the Over-Allotment Option, at the Offer Price per Share, to facilitate the return to Ximalaya of the 37,500,000 borrowed Shares which were used to cover the over-allocations in the International Placing.

There had been no purchase or sale of any Shares on the market for the purpose of price stabilization by the Stabilizing Manager during the stabilization period.

For further details of the full exercise of the Over-Allotment Option, please refer to the announcement of the Company dated December 27, 2017.

By order of the Board of Director
AK Medical Holdings Limited
Li Zhijiang
Chairman

Hong Kong, January 11, 2018

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Li Zhijiang, Ms. Zhang Bin, Mr. Zhang Chaoyang and Ms. Zhao Xiaohong as executive Directors, Mr. Li Wenming and Mr. Wang David Guowei as non-executive Directors, and Mr. Dang Gengting, Mr. Kong Chi Mo and Mr. Li Shu Wing David as independent non-executive Directors.